Agilent Technologies Inc. (NYSE:A) today announced the availability of
new ion
exchange and size exclusion columns specifically designed for the
analysis of bio-molecules including monoclonal antibodies, recombinant
proteins, peptides, vaccine products and DNA/RNA. The columns provide
robust, reproducible and high-resolution solutions for biopharmaceutical
manufacturers to effectively monitor the safety, efficacy and stability
of their products.
“The new columns greatly expand our current bio-columns
portfolio, which also include reverse phase columns for intact protein
separations and peptide mapping.”
“With the addition of these new bio-columns, we can now offer our
customers significant improvements in charge-based and size-based
analytical separations of bio-molecules,” said Helen Stimson, vice
president and general manager of Agilent’s Consumables and Supplies
Division. “The new columns greatly expand our current bio-columns
portfolio, which also include reverse phase columns for intact protein
separations and peptide mapping.”
Each new column is individually tested with protein samples to ensure
column-to-column and batch-to-batch reproducibility. The four new column
families and their benefits include: